KPV
Also known as: Lys-Pro-Val · Alpha-MSH tripeptide
KPV is a popular peptide topic online, but it is not FDA-approved for human use. Use this guide to understand the claims, the evidence gaps, and the safety questions to ask before considering anything further.
Compelling animal data for IBD and gut inflammation. Human clinical data is very limited. Growing interest from functional medicine for GLP-1 GI side effect management.
What to know before you go deeper
C-terminal tripeptide of alpha-MSH with potent anti-inflammatory effects. Acts on melanocortin receptors in the gut to reduce intestinal inflammation without systemic immunosuppression.
Approval status: Not FDA-approved. This is not an FDA-approved human treatment.
Inflammatory bowel disease, GLP-1-induced GI side effects, Gut permeability (leaky gut).
What evidence applies to my situation, what monitoring is needed, and what safer first steps should I try?
Why People Ask About KPV
- Inflammatory bowel disease
- GLP-1-induced GI side effects
- Gut permeability (leaky gut)
- Skin inflammation
Questions to Bring Up
No FDA-approved human therapeutic use. Discuss GI symptoms with a clinician and consider evidence-backed options before investigational peptides.
Dosing, sourcing, and suitability questions belong with a licensed clinician who can review your history, labs, medications, and goals.
Known Side Effects
- Generally well-tolerated in animal studies
- Limited human safety data
Important Safety Notes
⚠ Research use only
Particularly relevant for GLP-1 users experiencing persistent GI symptoms
Some researchers are interested in gut-specific applications, but human evidence remains limited
Often discussed with BPC-157 in gut-health wellness content
What Is Approved?
Research peptide — fragment of alpha-MSH. Not FDA-approved. Sometimes sold OTC as a supplement in some jurisdictions.
Your feedback helps us improve the guide.